FDA Approves Tepotinib for Metastatic NSCLC Harboring MET Exon 14 Skipping Alterations
The FDA has granted approval to tepotinib (Tepmetko) for adult patients with metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.
The FDA has granted approval to tepotinib (Tepmetko) for adult patients with metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.
Momelotinib achieved higher rates of transfusion independence compared with ruxolitinib.
Fuzuloparib with or without apatinib provided superior PFS benefit vs chemotherapy in HER2– metastatic breast cancer harboring germline BRCA1/2 mutations.
Christina Matousek, MSN, RN, OCN, of the Smilow Cancer Hospital at Yale New Haven Health, speaks about what Oncology Nursing Month, observed every May, means…
Drs. Thomas Zilli and Pierre Blanchard join The Uromigos at APCCC 2024 to debate the use of radiation therapy in prostate cancer and oligometastatic disease.
The U.S. Agency for International Development (USAID) is working toward a future where digital technology promotes inclusive growth, fosters resilient and democratic societies, and empowers…
Mohamad Mohty, MD, PhD, highlights key takeaways from the 50th Annual EMBT Meeting, focusing on ongoing efforts within the GVHD treatment arena.
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
AbstractLeadless pacemaker implantation is recognized as safe and effective for treating bradycardia. However, there are limited descriptions of its use in patients with complex anatomical…
WASHINGTON (May 9, 2024) — JACC, the flagship journal of the American College of Cardiology, and The Lancet are bringing together their resources, expertise, and…
Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.